The pill, from HRA Pharma, would be the first hormonal birth control to be sold without a prescription if approved. You have undefined articles remaining that you can gift this month. - are separated with a comma, semicolon or space ([email protected],…
Joseph reported this story from Munich and Tübingen, Germany. Presidential sessions at top cancer meetings typically feature practice-changing clinical trials, detailed in front of thousands of global experts packed into rooms so cavernous they merit their own ZIP codes. But…
(Washington Examiner) In light of an FDA-purported review of chemical abortion pills, it’s important to note that information currently with the Environmental Protection Agency is extremely relevant. The public’s exposure to an endocrine disruptor in our drinking water deserves consideration.
Brussels: The European Commission has made legally binding a set of commitments offered by French pharmaceutical company Sanofi to address preliminary concerns over potentially misleading communications about a competing influenza vaccine in Germany and France. The case centres on Fluad,…
The European Commission has made commitments offered by Sanofi legally binding under EU antitrust rules. The commitments relate to the Commission's preliminary competition concerns relating to Sanofi's alleged disparagement campaigns in Germany and France against Fluad, the only enhanced flu…
WASHINGTON (BP) – The Food and Drug Administration (FDA) has postponed until perhaps March 2027 the release of a safety study on the abortion pill mifepristone, delaying any attempts to end telehealth prescriptions for the drug. The FDA announced the delay in…
WASHINGTON (OSV News) — The Food and Drug Administration’s safety review of mifepristone is expected to stretch into next year, according to an Oct. 7 court filing, prompting disappointment from pro-life groups. In a court-ordered status update on the review, the FDA…
Lexaria Bioscience Corp. had received ethics approval from an independent review board, for Human Pilot Study #7 that will evaluate two oral DehydraTECH-semaglutide compositions against Novo... had received ethics approval from an independent review board, for Human Pilot Study #7 (GLP-1-H26-7) that…
The Food and Drug Administration faces a court-ordered Oct. 7 deadline to update its study of the abortion drug mifepristone, and pro-life leaders say that review will fail women unless it counts the injuries already on record. SBA Pro-Life America President…
Fidson Healthcare Plc, a Nigerian pharmaceutical manufacturer, has been selected by the Medicines Patent Pool (MPP) as one of 11 manufacturers that will develop and produce generic versions of Roche’s baloxavir marboxil, potentially expanding access to the influenza treatment across 129 eligible…
FDA/EMA decisions, boxed warnings, pharmacovigilance, and label changes.
An article joins this feed when it matches these terms. Each one is also a search of its own.